SLC12A5 and central nervous system cancer: By combining the expression of GABAA receptor and SLC12A5 to divide glioma patients into four groups, we found that OS of patients could be obviously distinguished under this stratification in which patients with high expression of GABAA receptor and SLC12A5 had the best outcome (Figure 7C).